Clone:
REAL687
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF

Extended validation for CD99 Antibody, anti-human,
REAlease
®

Specificity

Knockout validation
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
WT
KO
View details
Fluorescence microscopy image of CD99 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD99-PE (REAL687, red) and counterstained with DRAQ5 (blue) as DNA stain.
View details
Fluorescence microscopy image of CD99 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD99-PE (REAL687, red) and counterstained with DRAQ5 (blue) as DNA stain.
Fluorescence microscopy image of CD99 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD99-PE (REAL687, red) and counterstained with DRAQ5 (blue) as DNA stain.
View details
Overlay histogram showing flow cytometric analysis of CD99 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD99-PE, clone (REAL687). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Overlay histogram showing flow cytometric analysis of CD99 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD99-PE, clone (REAL687). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD99 Antibody, anti-human,
REAlease
®

Overview

Clone REAL687 is an antibody fragment derived from the full CD99 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL687 recognizes the human CD99 antigen, a 32 kDa type I single chain transmembrane sialoglycoprotein which is also known as E2 antigen or MIC2. The expression level of CD99 is particularly high in thymocytes, T cells, T cell leukemias and lymphomas, subsets of mature plasma cells in the medullary cord of reactive lymph nodes, pancreatic islet cells, granulosa cells of the ovary, Sertoli cells of the testes, but absent on granulocytes. It is involved in T cell–adhesion processes and in spontaneous rosette formation with erythrocytes. CD99 plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane and it acts at the same site as, but independently of, PECAM1. It also have the ability to rearrange the actin cytoskeleton and act as an oncosuppressor in osteosarcoma.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Detailed product information

Technical specifications

CloneREAL687
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD99
Distribution of antigenT cells, thymocytes, plasma cells, leukemia cells, pan T cells, other
RRIDAB_2819734, AB_2857726, AB_2857724, AB_2819735

Resources for CD99 Antibody, anti-human,
REAlease
®

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

Seems like you are coming from USA!
Do you want to visit our website in your country?